Literature DB >> 35676539

Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.

Bryan J Fraser1,2, Serap Beldar3, Almagul Seitova3, Ashley Hutchinson3, Dhiraj Mannar4, Yanjun Li3, Daniel Kwon1,2, Ruiyan Tan1, Ryan P Wilson1, Karoline Leopold4, Sriram Subramaniam4, Levon Halabelian5,6, Cheryl H Arrowsmith7,8,9, François Bénard10,11.   

Abstract

Transmembrane protease, serine 2 (TMPRSS2) has been identified as key host cell factor for viral entry and pathogenesis of SARS-CoV-2. Specifically, TMPRSS2 proteolytically processes the SARS-CoV-2 Spike (S) protein, enabling virus-host membrane fusion and infection of the airways. We present here a recombinant production strategy for enzymatically active TMPRSS2 and characterization of its matured proteolytic activity, as well as its 1.95 Å X-ray cocrystal structure with the synthetic protease inhibitor nafamostat. Our study provides a structural basis for the potent but nonspecific inhibition by nafamostat and identifies distinguishing features of the TMPRSS2 substrate binding pocket that explain specificity. TMPRSS2 cleaved SARS-CoV-2 S protein at multiple sites, including the canonical S1/S2 cleavage site. We ranked the potency of clinical protease inhibitors with half-maximal inhibitory concentrations ranging from 1.4 nM to 120 µM and determined inhibitor mechanisms of action, providing the groundwork for drug development efforts to selectively inhibit TMPRSS2.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35676539     DOI: 10.1038/s41589-022-01059-7

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   16.174


  41 in total

1.  Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

Authors:  D E Afar; I Vivanco; R S Hubert; J Kuo; E Chen; D C Saffran; A B Raitano; A Jakobovits
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway.

Authors:  Karin List; Peter Kosa; Roman Szabo; Alexandra L Bey; Chao Becky Wang; Alfredo Molinolo; Thomas H Bugge
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

3.  TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.

Authors:  Adeline Heurich; Heike Hofmann-Winkler; Stefanie Gierer; Thomas Liepold; Olaf Jahn; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

4.  Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.

Authors:  Shoichiro Mukai; Kenji Yorita; Yukari Kawagoe; Yuichi Katayama; Kozue Nakahara; Toyoharu Kamibeppu; Satoru Sugie; Hiromasa Tukino; Toshiyuki Kamoto; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2014-09-04       Impact factor: 4.174

5.  Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin.

Authors:  Tiffany Tang; Javier A Jaimes; Miya K Bidon; Marco R Straus; Susan Daniel; Gary R Whittaker
Journal:  ACS Infect Dis       Date:  2021-01-12       Impact factor: 5.084

6.  SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells.

Authors:  Michihito Sasaki; Kentaro Uemura; Akihiko Sato; Shinsuke Toba; Takao Sanaki; Katsumi Maenaka; William W Hall; Yasuko Orba; Hirofumi Sawa
Journal:  PLoS Pathog       Date:  2021-01-21       Impact factor: 6.823

7.  SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress.

Authors:  Wasco Wruck; James Adjaye
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

8.  Integrated decoding hematopoiesis and leukemogenesis using single-cell sequencing and its medical implication.

Authors:  Pengfei Qin; Yakun Pang; Wenhong Hou; Ruiqing Fu; Yingchi Zhang; Xuefei Wang; Guofeng Meng; Qifa Liu; Xiaofan Zhu; Ni Hong; Tao Cheng; Wenfei Jin
Journal:  Cell Discov       Date:  2021-01-05       Impact factor: 10.849

9.  Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease.

Authors:  Ce Zhang; Yikai Zhang; Shengnan Zhang; Zhiting Wang; Shijin Sun; Meng Liu; Yue Chen; Ningzheng Dong; Qingyu Wu
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

10.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

View more
  5 in total

1.  Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.

Authors:  Lukas Wettstein; Philip Maximilian Knaff; Christian Kersten; Patrick Müller; Tatjana Weil; Carina Conzelmann; Janis A Müller; Maximilian Brückner; Markus Hoffmann; Stefan Pöhlmann; Tanja Schirmeister; Katharina Landfester; Jan Münch; Volker Mailänder
Journal:  Commun Biol       Date:  2022-07-08

2.  Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases.

Authors:  Akmaral Assylbekova; Anuar Zhanapiya; Renata Grzywa; Marcin Sienczyk; Christian Schönbach; Timo Burster
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-20

3.  Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.

Authors:  Jonathan H Shrimp; John Janiszewski; Catherine Z Chen; Miao Xu; Kelli M Wilson; Stephen C Kales; Philip E Sanderson; Paul Shinn; Rick Schneider; Zina Itkin; Hui Guo; Min Shen; Carleen Klumpp-Thomas; Samuel G Michael; Wei Zheng; Anton Simeonov; Matthew D Hall
Journal:  ACS Infect Dis       Date:  2022-06-01       Impact factor: 5.578

4.  Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection.

Authors:  Flavio De Maio; Mariagrazia Rullo; Modesto de Candia; Rosa Purgatorio; Gianfranco Lopopolo; Giulia Santarelli; Valentina Palmieri; Massimiliano Papi; Gabriella Elia; Erica De Candia; Maurizio Sanguinetti; Cosimo Damiano Altomare
Journal:  Viruses       Date:  2022-08-05       Impact factor: 5.818

5.  SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK.

Authors:  Sona Aramyan; Kirk McGregor; Samarth Sandeep; Angela Haczku
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.